Franklin Resources
ENGN icon

Franklin Resources’s enGene Therapeutics ENGN Stock Holding History

Franklin Resources’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,314,993
Closed -$8.96M – 3242
2026
Q1 		$8.96M Sell
1,314,993
-73,007
-5% -$650K ﹤0.01% 1283
2025
Q4 		$12.5M Buy
1,388,000
+350,000
+34% +$2.8M ﹤0.01% 1093
2025
Q3 		$7.09M Hold
1,038,000
– – ﹤0.01% 1289
2025
Q2 		$3.78M Sell
1,038,000
-136,866
-12% -$514K ﹤0.01% 1470
2025
Q1 		$5.26M Sell
1,174,866
-15,086
-1% -$93.7K ﹤0.01% 1324
2024
Q4 		$7.91M Hold
1,189,952
– – ﹤0.01% 1195
2024
Q3 		$9.19M Buy
1,189,952
+389,918
+49% +$2.9M ﹤0.01% 1158
2024
Q2 		$7.54M Buy
800,034
+34
+0% +$436 ﹤0.01% 1175
2024
Q1 		$13.6M Buy
+800,000
New +$9.79M ﹤0.01% 979

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Franklin Resources's ENGN Position: Q2 2026 in Review

Franklin Resources sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 1,314,993 shares — an estimated $8.96M sold.

Franklin Resources first reported a position in ENGN in Q1 2024 and held it in 9 quarters. The position peaked at $13.6M in Q1 2024. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Franklin Resources reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Franklin Resources sold 1,314,993 enGene Therapeutics shares in Q2 2026, an estimated $8.96M.
  • Franklin Resources first reported a position in enGene Therapeutics in Q1 2024 and held it in 9 quarters.
  • Franklin Resources's enGene Therapeutics position peaked at $13.6M in Q1 2024.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.